Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 10/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | NSD1 | Q96L73 | 1/20 | 0.34 |
| ▸ | THRA | P10827 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4139303 | 0.85 | HSD17B10 (0.50) | FBP1MAPTCYP3A4TDP1ALDH1A1 | |
| SCHEMBL4128702 | 0.82 | NPC1 (0.42) | FBP1MAPTCYP3A4TDP1CYP2C19 | |
| SCHEMBL4138689 | 0.82 | ALDH1A1 (0.50) | FBP1MAPTCYP3A4TDP1ALDH1A1 | |
| SCHEMBL4123151 | 0.82 | NSD1 (0.51) | FBP1MAPTCYP3A4TDP1CYP2C19 | |
| SCHEMBL4140328 | 0.81 | FBP1 (0.44) | FBP1MAPTCYP3A4TDP1CYP2C19 | |
| SCHEMBL4124630 | 0.80 | CYP2C19 (0.41) | FBP1MAPTCYP2C19ALDH1A1LMNA | |
| SCHEMBL9722840 | 0.79 | CYP3A4 (0.58) | MAPTCYP3A4TDP1CYP1A2CYP2C19 | |
| SCHEMBL4127768 | 0.77 | HTT (0.41) | FBP1MAPTCYP3A4TDP1 | |
| SCHEMBL4289343 | 0.76 | TDP1 (0.56) | FBP1MAPTCYP3A4TDP1ALDH1A1 | |
| SCHEMBL30189770 | 0.75 | CYP3A4 (0.60) | CYP3A4TDP1CYP1A2CYP2C19ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090192121-A1 | NOVEL BISAMIDATE PHOSPHONATE PRODRUGS | JIANG TAO | 2009-07-30 | — | — | US | disclosed |
| US-6965033-B2 | Bisamidate phosphonate prodrugs | METABASIS THERAPEUTICS, INC. (US) | 2005-11-15 | — | — | US | disclosed |
| US-20050004077-A1 | Novel bisamidate phosphonate prodrugs | JIANG TAO (US) | 2005-01-06 | — | — | US | disclosed |
| US-20020173490-A1 | Novel bisamidate phosphonate prodrugs | METABASIS THERAPEUTICS, INC. | 2002-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020173490-A1 | Novel bisamidate phosphonate prodrugs | FBP1, PFKFB1, G6PC1 | FBP1 1/4885MAPT 2026/4885CYP3A4 1052/4885 |
| US-20050004077-A1 | Novel bisamidate phosphonate prodrugs | FBP1, PFKFB1, PFKFB2 | FBP1 1/4885MAPT 1651/4885CYP3A4 1082/4885 |
| US-20090192121-A1 | NOVEL BISAMIDATE PHOSPHONATE PRODRUGS | FBP1, PFKFB1, PFKFB2 | FBP1 1/4885MAPT 1651/4885CYP3A4 1082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.